Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Product/Service, Trade Show

New Clinical Results from the Acessa System to be Presented at AAGL Global Congress on Minimally Invasive Gynecology

Acessa Health Inc., developer of the Acessa ProVu® System, announced today that clinical results after the Acessa Procedure will be the focus of two presentations at the 2019 American Association of Gynecologic Laparoscopists (AAGL) Global Congress on Minimally Invasive Gynecology Nov. 11-13, 2019 in Vancouver.

The Acessa Procedure is specifically designed to treat women suffering from uterine fibroids and is clinically proven with long-term data as a safe alternative to hysterectomy and myomectomy. Over 3,000 procedures have been performed to-date. Acessa ProVu® is the third generation of Acessa's minimally invasive, laparoscopic radiofrequency ablation solution ? and is the first and only solution with a category 1 CPT reimbursement code and widely established coverage. It has been the subject of 47 peer-reviewed publications across 850 study patients.

"Twenty nineteen has been a pivotal year for Acessa Health with the availability of the Acessa ProVu® System and the growing demand from physicians and women who see the benefits of this treatment option for fibroids," said Kim Rodriguez, President and CEO, Acessa Health. "The presentations at AAGL showcase the growing amount of real-world clinical evidence as well as the proven safety of the procedure."

The presentations include:

In addition, Soyini Hawkins, M.D., and a panelist of Acessa users presented a case study using pre-recorded surgical video footage at a professional education event on Sunday. The well-attended event highlights the company's intense focus on educating physicians who care for women suffering from uterine fibroids.

About the Acessa Procedure

Unlike many alternative interventions, the Acessa Procedure can treat nearly all sizes and locations of fibroids ? including those outside the uterine cavity and within the uterine walls. The Acessa Procedure is a minimally invasive, outpatient treatment that involves two small incisions and uses radiofrequency ablation (i.e., heat) to destroy each targeted fibroid by applying controlled energy through a small needle array. The treated tissue may then be completely reabsorbed. There is no cutting or suturing of uterine tissue. Patients experience minimal post-procedure discomfort and typically return to normal activities in 3-5 days.

About Acessa Health Inc.

Acessa Health is a women's health innovator dedicated to advancing minimally invasive, uterine-sparing solutions for women with symptomatic fibroids. The company introduced the use of radiofrequency ablation for the treatment of uterine fibroids, under laparoscopic ultrasound guidance, and is continuing to develop technologies that give women more options. Acessa Health's headquarters are in Austin, Texas. For more information, visit AcessaProcedure.com.


Insufficient data exist on which to evaluate the safety and effectiveness of Acessa procedure in women who plan future pregnancy. Therefore, the Acessa procedure is not recommended for women who are planning future pregnancy.

These press releases may also interest you

at 09:10
Using online estimates will tell the policyholders if they still pay fair prices for their coverage. Comparing prices from multiple companies will help drivers have a better view of the market. When shopping online, it is important to follow the next...

at 09:00
On February 18, 2020, the second online course of ALLPCB, Four-Step Method of WeChat Marketing, arrived as scheduled. Led by the director of Training Center, jointly researched by Training Center and Sales Center, this course aims to provide sales...

at 08:26
Phoenix Contact, a digital industrial company is set to participate at the upcoming Middle East Energy Exhibition (formerly known as Middle East Electricity), the global energy platform. The Phoenix Contact stand will be located at booth number 6A10...

at 07:00
From RSA 2020, Wallarm has released an expanded set of parsers, detection of API-specific vulnerabilities and API schema analysis for gRPC and GraphQL. With Wallarm context-specific protection is delivered both for externally-facing APIs and for...

at 06:49
Cellcom Israel Ltd. (the "Company") announced today that Mr. Ami Erel, the Company's Chairman of the Board of Directors, informed the Company of his resignation from the board of directors, effective March 1, 2020. About Cellcom Israel Cellcom...

22 fév 2020
Sky Seal Capital announces Phoenix Lending, a platform that allows users to deposit digital asset and earn interest. Phoenix Lending has been launched from February 1 to March 1 in several phases introducing products of different annualized...

News published on 11 november 2019 at 08:05 and distributed by: